Electronic Triggers: Microhematuria Trigger

Hematuria Clinical Trial

Official title:

Electronic Trigger for Microhematuria

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05011253
• Other study ID #: QI-MH
• Status: Completed
• Phase: N/A
• Start date: October 6, 2021
• Est. completion date: June 6, 2022

Study information

• Verified date: July 2022
• Source: NYU Langone Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The research team will evaluate the effectiveness of an InBasket Results message that prompts providers to place appropriate follow up orders.

Description:

The research team will evaluate the effectiveness of an InBasket Results message that prompts providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2000
• Est. completion date: June 6, 2022
• Est. primary completion date: December 6, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years and older

Eligibility

Inclusion Criteria:

• 35 years of age or older

• 3+ RBC on Urinalysis

• Urinalysis sent during an outpatient encounter

• any of the following: 60 years of age or older; RBC > 25; current or prior tobacco use; Gross Hematuria

Exclusion Criteria:

• Under 35 years of age

• Cystoscopy within 1 year prior to Urinalysis

• Nitrite positive AND Leukocyte Esterase positive

• Nitrite positive AND >100 WBC

• Leukocyte Esterase positive AND >100 WBC

• Know GU cancer diagnosis

• Urinalysis ordered by urology provider

Related Conditions & MeSH terms

• Hematuria

Intervention

Other:
• Electronic Trigger Microhematuria Alert
To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).

Locations

Country	Name	City	State
United States	NYU Langone	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation rate	Urology evaluation with cystoscopy and appropriate imaging	180 days of alert